Classification and decomposition of quaternionic projective transformations
Linear Algebra and its Applications · 2023-11 · 676 · 66-87
DOI: 10.1016/j.laa.2023.07.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Linear Algebra and its Applications, 2023-11. Verfasst von Sandipan Dutta und 2 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Council of Scientific and Industrial Research, India, Science and Engineering Research Board.
Abstract (Originalsprache)
We consider the projective linear group $\mathrm{PSL}(3,\mathbb{H})$. We have investigated the reversibility problem in this group and use the reversibility to offer an algebraic characterization of the dynamical types of $\mathrm{PSL}(3,\mathbb{H})$. We further decompose elements of $\mathrm{SL}(3,\mathbb{H})$ as products of simple elements, where an element $g$ in $\mathrm{SL}(3,\mathbb{H})$ is called $\textit{simple}$ if it is conjugate to an element of $\mathrm{SL}(3,\mathbb{R})$. We have also revisited real projective transformations and following Goldman's ideas, have offered a complete classification for elements of $\mathrm{SL }(3,\mathbb{R})$.
Förderung
- Council of Scientific and Industrial Research, India
- Science and Engineering Research Board
Zitieren
APA
Dutta, S., Gongopadhyay, K., & Lohan, T. (2023). Classification and decomposition of quaternionic projective transformations. Linear Algebra and its Applications, 676, 66-87. https://doi.org/10.1016/j.laa.2023.07.003
Vancouver
Dutta S, Gongopadhyay K, Lohan T. Classification and decomposition of quaternionic projective transformations. Linear Algebra and its Applications. 2023;676:66-87. doi:10.1016/j.laa.2023.07.003
BibTeX
@article{Dutta2023,
author = {Dutta, Sandipan and Gongopadhyay, Krishnendu and Lohan, Tejbir},
title = {Classification and decomposition of quaternionic projective transformations},
journal = {Linear Algebra and its Applications},
year = {2023},
volume = {676},
pages = {66--87},
doi = {10.1016/j.laa.2023.07.003}
}
EUVIMED